420 related articles for article (PubMed ID: 35303962)
21. The tricks for fighting against cancer using CAR NK cells: A review.
Vahidian F; Khosroshahi LM; Akbarzadeh M; Jahanban-Esfahlan A; Baghbanzadeh A; Ali-Hassanzadeh M; Safarzadeh E
Mol Cell Probes; 2022 Jun; 63():101817. PubMed ID: 35436564
[TBL] [Abstract][Full Text] [Related]
22. CAR-NK Cells for Cancer Therapy: Molecular Redesign of the Innate Antineoplastic Response.
Cienfuegos-Jimenez O; Vazquez-Garza E; Rojas-Martinez A
Curr Gene Ther; 2022; 22(4):303-318. PubMed ID: 34923939
[TBL] [Abstract][Full Text] [Related]
23. Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential.
Wang X; Yang X; Yuan X; Wang W; Wang Y
Exp Hematol Oncol; 2022 Nov; 11(1):85. PubMed ID: 36324149
[TBL] [Abstract][Full Text] [Related]
24. Natural killer cells: of-the-shelf cytotherapy for cancer immunosurveillance.
Zhang L; Liu M; Yang S; Wang J; Feng X; Han Z
Am J Cancer Res; 2021; 11(4):1770-1791. PubMed ID: 33948388
[TBL] [Abstract][Full Text] [Related]
25. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
Rezvani K; Rouce RH
Front Immunol; 2015; 6():578. PubMed ID: 26635792
[TBL] [Abstract][Full Text] [Related]
26. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
27. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
[TBL] [Abstract][Full Text] [Related]
28. Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future?
Liu F; Miao X; Han L; Song X
Front Oncol; 2024; 14():1390006. PubMed ID: 38863635
[TBL] [Abstract][Full Text] [Related]
29. CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer.
Włodarczyk M; Pyrzynska B
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612114
[TBL] [Abstract][Full Text] [Related]
30. Advantages and applications of CAR-expressing natural killer cells.
Glienke W; Esser R; Priesner C; Suerth JD; Schambach A; Wels WS; Grez M; Kloess S; Arseniev L; Koehl U
Front Pharmacol; 2015; 6():21. PubMed ID: 25729364
[TBL] [Abstract][Full Text] [Related]
31. CAR-NK cell in cancer immunotherapy; A promising frontier.
Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
[TBL] [Abstract][Full Text] [Related]
32. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
33. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
[TBL] [Abstract][Full Text] [Related]
34. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
35. Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia.
Gurney M; O'Dwyer M
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805422
[TBL] [Abstract][Full Text] [Related]
36. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
37. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
Mehta RS; Rezvani K
Front Immunol; 2018; 9():283. PubMed ID: 29497427
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor engineered natural killer cells for cancer therapy.
Zhang Y; Zhou W; Yang J; Yang J; Wang W
Exp Hematol Oncol; 2023 Aug; 12(1):70. PubMed ID: 37563648
[TBL] [Abstract][Full Text] [Related]
39. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
Hu Y; Tian ZG; Zhang C
Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014
[TBL] [Abstract][Full Text] [Related]
40. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells.
Herrera L; Santos S; Vesga MA; Anguita J; Martin-Ruiz I; Carrascosa T; Juan M; Eguizabal C
Sci Rep; 2019 Dec; 9(1):18729. PubMed ID: 31822751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
